» Articles » PMID: 22338049

The Role of CD19 and CD27 in the Diagnosis of Multiple Myeloma by Flow Cytometry: a New Statistical Model

Overview
Specialty Pathology
Date 2012 Feb 17
PMID 22338049
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

We have developed a new statistical diagnostic model that examines the correlation between immunophenotype and clonality as detected by flow cytometry (FC) and histology, defining the diagnostic role of FC in multiple myeloma (MM). The 192 bone marrow samples from patients and control subjects were studied for routine diagnostic analysis of MM; a minimum of 100 plasma cells (PCs) were analyzed for each patient sample. A direct 7- or 8-color method was applied to study the immunophenotype of PCs, utilizing a FACSCanto II (BD Biosciences, San Jose, CA). Samples were labeled with fluorochrome-conjugated monoclonal antibodies (AmCyan, Pac Blue, fluorescein isothiocyanate, phycoerythrin [PE], PECy7, peridinin-chlorophyll protein, allophycocyanin [APC], and APC-Cy7) to the following antigens: CD138, CD81, CD200, CD221, CD45, CD38, CD28, CD19, CD27, CD117, CD38, CD33, CD20, CD56, CD10, and immunoglobulin κ and λ light chains. Among all antigens tested, CD19 and CD27, when applied to our model, resulted in optimal concordance with histology. This model defines the effective diagnostic role FC could have in MM and in the detection of minimal residual disease.

Citing Articles

[Chinese expert consensus on the application of flow cytometry for the detectin of circulating plasma cells in plasma cell disorders (2024)].

Zhonghua Xue Ye Xue Za Zhi. 2024; 45(4):313-321.

PMID: 38951057 PMC: 11167996. DOI: 10.3760/cma.j.cn121090-20240117-00026.


Plasma Cell Leukemia-Clinicopathological Profile from a Tertiary Care Center in Western India.

Manimaran P, Rai V, Ranka R, Sawhney J South Asian J Cancer. 2023; 12(3):280-285.

PMID: 38047050 PMC: 10691916. DOI: 10.1055/s-0043-57231.


Immune microenvironment characteristics in multiple myeloma progression from transcriptome profiling.

Wang J, Hu Y, Hamidi H, Dos Santos C, Zhang J, Punnoose E Front Oncol. 2022; 12:948548.

PMID: 36033464 PMC: 9413314. DOI: 10.3389/fonc.2022.948548.


Histamine receptor 2 blockade selectively impacts B and T cells in healthy subjects.

Meghnem D, Oldford S, Haidl I, Barrett L, Marshall J Sci Rep. 2021; 11(1):9405.

PMID: 33931709 PMC: 8087813. DOI: 10.1038/s41598-021-88829-w.


B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma.

Abramson H Int J Mol Sci. 2020; 21(15).

PMID: 32707894 PMC: 7432930. DOI: 10.3390/ijms21155192.